You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
A small study suggests fecal transplants could increase the number of cancer patients who respond to immunotherapy, according to LiveScience.
The Phase II trial will use OmniSeq's RNA-seq assay to determine whether patients should be treated with one of two agents combined with BMS' nivolumab.
In PNAS this week: droplet-based mRNA sequencing strategy, secretome mouse model, and more.
In a genome-wide association study of Takayasu arteritis, researchers uncovered disease-linked loci both within and beyond the HLA region.
Adaptive is rebranding its immunoSeq Dx assay as T-Detect and plans to submit for an EUA for a COVID-19 T-Cell response test by the end of the year.
In PNAS this week: genetic evidence for Inca resettlement, analysis of spermatogonial stem cell transcriptomes, and more.
In PNAS this week: concerns regarding proposed SARS-CoV-2 phylogenetic network, adaptations that help Enterococcus establish infections, and more.
In PNAS this week: mapping of ancient human migrations in Europe, recurrent gene fusion in breast cancer, and more.
Researchers from Trinity College Dublin and the University of Pittsburgh look into how often de novo genes arise and how important they may be.
The program aims to consent up to 150,000 patients to a larger biobank program and return selective preemptive PGx results through their medical center physicians.
Politico reports that the NYPD DNA database has grown since it announced it would be removing profiles from it.
Forbes reports that a structural biology lab at Oxford University studying the coronavirus was hacked.
Science reports that a Dutch research funding agency is combating a ransomware attack.
In Science this week: set of 64 haplotype assemblies from 32 individuals, and more.